Healthcare Research Industry Reports’ Post

Particle Therapy Market worth $ 1.1 billion by 2028 Download Complete PDF:-https://lnkd.in/dr6wJN7D The global particle therapy market in terms of revenue was estimated to be worth $0.7 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 8.2% from 2023 to 2028. Particle therapy market: Market Dynamics -Driver: Growing global prevalence of cancer -Increasing number of particle therapy centers worldwide -Restraint: Affordability and accessibility of treatments -Opportunity: Rising healthcare expenditure across developing countries As of 2022, prominent players in the market are IBA (EU), Varian Medical Systems Pacific Inc (US), and Hitachi (Japan), among others. #ParticleTherapy #ProtonTherapy #CancerTreatment #RadiationTherapy #OncologySolutions #AdvancedRadiotherapy #MedicalPhysics #CancerCare #HadronTherapy #HealthcareInnovation

#Review NIR-II Aggregation-Induced Emission Luminogens for Tumor Phototheranostics by Yonghong Tan, Peiying Liu, Danxia Li, Dong Wang and Ben Zhong Tang https://lnkd.in/d-HWYByq MDPI Shenzhen University The University of Hong Kong #NIRIIemission #phototheranostics #cancertreatment #openaccess #Abstract As an emerging and powerful material, aggregation-induced emission luminogens (AIEgens), which could simultaneously provide a precise diagnosis and efficient therapeutics, have exhibited significant superiorities in the field of phototheranostics. Of particular interest is phototheranostics based on AIEgens with the emission in the range of second near-infrared (NIR-II) range (1000–1700 nm), which has promoted the feasibility of their clinical applications by virtue of numerous preponderances benefiting from the extremely long wavelength. In this minireview, we summarize the latest advances in the field of phototheranostics based on NIR-II AIEgens during the past 3 years, including the strategies of constructing NIR-II AIEgens and their applications in different theranostic modalities (FLI-guided PTT, PAI-guided PTT, and multimodal imaging-guided PDT–PTT synergistic therapy); in addition, a brief conclusion of perspectives and challenges in the field of phototheranostics is given at the end.

The clinical role of tumor volume expressing PSMA, segmentation tools, RECIP criteria for the evaluation of response to taxane-based therapies, how to select patients for RLT: these are the topics of our talk in Hamburg!!! Thanks to Hermes Medical Solutions for the possibility to talk about our projects on #prostatecancerpatients in collaboration with IEO Istituto Europeo di Oncologia and John Hopkins University. #eanm24 #theranostic #PSMA RECIP Criteria Francesco Ceci

Have your ever heard of immunogenic cell death (ICD)? Our PhD student Egor Matnurov will explain it to you in his video. ✍ ICD-inducing agents can trigger localized cell death and induce an immune response to potentially overcome metastatic and relapsing tumors. ✍Do metal complexes, based on platinum, ruthenium, irhidium, have clinical potential as ICD-inducing therapeutic agents? If you want to know more about it, watch our video and read this review: L. Zhang, N. Montesdeoca, J. Karges, H. Xiao, Angew. Chem. Int. Ed. 2023, 62, e202300662 #ICD #immunogeniccelldeath #immunotherapy #immunesystem #anticancerdrugs #research

🚨 Exciting Webinar Alert! 🚨 Join us on November 27th, 2024 for a deep dive into the cutting-edge world of Peptide-Drug Conjugates (PDCs) for the precise treatment of Pulmonary Fibrosis! 🎤 Presented by Dr. Kelly Bugatti from the University of Parma, Italy, this session will explore the latest advancements in targeted therapy using PDCs, designed to selectively deliver nintedanib (a potent kinase inhibitor) for the treatment of pulmonary fibrosis. 🧬 Key Topics: · Understanding the mechanism of PDCs · How PDCs can revolutionize drug delivery for pulmonary fibrosis · In vitro and in vivo evaluations of promising PDC candidates 🔬 Don’t miss this unique opportunity to stay ahead of the curve in biomedical research! 👉 REGISTER NOW: https://lnkd.in/gtrcVJXy 🗓️ November 27, 2024 🕙 10:00 EST | 16:00 CET 🔗 https://lnkd.in/gcKvT_PX #BOCSciences #Webinar #PeptideDrugConjugates #PulmonaryFibrosis #TargetedTherapy #BiomedicalResearch #ScienceWebinar

In this month's AR issue, Kwanghee Kim and Hee Jin Lee, among others from Asan Medical Center (AMC), analyzed #chemokine #receptor expression in activated #Tcells and identified low expression of #CCR10. They then generated 1G4 T-cell receptor-engineered T cells with CCR10, which exhibited enhanced #trafficking and anti-tumor effects both #invitro and #invivo. This study highlights the potential of CCR10 for developing efficient adoptive T-cell treatments targeting #solid #tumors. Read the full study here: https://lnkd.in/dDE3VeHP #immunotherapy #cancerimmunotherapy #cancertreatment #CCL28 #xenograft #tumormicroenvironment

Digital PCR is a precise technique for identifying and quantifying nucleic acids by determining precise molecule amounts through statistical methods. Digital PCR allows for precise, fast, and straightforward detection of molecules. Also, it has higher sensitivity and facilitates absolute quantification of molecule levels. 🧪🧬 Technological advancements, which have improved the precision and sensitivity of nucleic acid quantification, drive the market demand. Besides, the increasing prevalence of cancer is anticipated to have a significant impact on market expansion. 🔬📈 The proficient team at Polaris Market Research has done an in-depth analysis of the digital PCR market. Our comprehensive research report thoroughly examines the market and covers all your needs. 𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞 𝐭𝐨 𝐠𝐞𝐭 𝐚 𝐟𝐫𝐞𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐫𝐞𝐩𝐨𝐫𝐭 𝐧𝐨𝐰! 💻📃 https://lnkd.in/deyaiSsj #digitalpcr #healthcare #polymerasechainreactionmarket #clinicaldiagnostics #polarismarketresearch

One of the research directions of our group is the development of novel #therapeutic agents capable of activating #immune system in #cancer #patients. These agents are called ICD inducers. We will dedicate this week to the overview of the recent findings in the field of metal-based ICD inducers. Stay tuned for our monthly newsletter to know more about our own ICD-inducing drug candidates. #ICD #immunogeniccelldeath #immunotherapy #immunesystem #anticancerdrugs #research

Relapse Multiple Myeloma (MM) patients urgently need more effective therapies. Vrije Universiteit Amsterdam (VU Amsterdam) Takeda Molecular Templates publish a nice study on the development of a toxin body (CD38 scFv linked to Shiga-like toxin A) synthesized by ATUM. The toxin body its internalized and the Shiga-like toxin cause cell death to MM cells with minimal toxicity to non-MM cells. Toxin body also show efficient in-vivo activity in mouse xenograft models. https://lnkd.in/gvRw8Kab

𝗜𝗼𝗻𝗽𝗮𝘁𝗵 𝗖𝘂𝘀𝘁𝗼𝗺𝗲𝗿𝘀 𝗦𝗵𝗼𝘄𝗰𝗮𝘀𝗲 𝗚𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝘀 𝗶𝗻 𝗧𝗶𝘀𝘀𝘂𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘄𝗶𝘁𝗵 𝗠𝗜𝗕𝗜+𝗠𝗔𝗟𝗗𝗜 𝗮𝘁 𝗔𝗦𝗠𝗦 𝟮𝟬𝟮𝟰 Exciting news! At last month's ASMS 2024, Ionpath customers were at the forefront of innovation, presenting five abstracts highlighting groundbreaking advancements achieved by combining Multiplexed Ion Beam Imaging (MIBI) and Matrix-assisted laser desorption/ionization (MALDI). This innovative approach is empowering researchers to revolutionize complex biological studies, offering: 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗧𝗶𝘀𝘀𝘂𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀: Combining MIBI with MALDI allows simultaneous extraction of untargeted molecular composition and targeted single-cell phenotypes from the same sample. 𝗛𝗶𝗴𝗵-𝗥𝗲𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: This integration provides detailed insights into tumor microenvironments, immune-tumor interactions, and biomarker identification, aiding personalized medicine. 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗗𝗶𝘀𝗲𝗮𝘀𝗲: Understanding and Treatment: The approach accelerates drug development, optimizes combination therapies, and enhances understanding of disease mechanisms, leading to more effective, tailored treatment strategies. These advancements, championed by our valued customers, demonstrate the immense potential of this powerful combination across various scientific fields. Learn more about how MIBI can revolutionize your tissue analysis: https://lnkd.in/gFtDzVBh #MIBIscope #TissueAnalysis #ASMS2024 #ScientificResearch #CustomerSuccess #Breakthrough